brachyury 2 Inhibitors
Brachyury 2, a member of the T-box transcription factor family, plays a pivotal role in embryonic development, particularly in mesoderm formation and differentiation. This protein is crucial for the specification of the notochord, a defining structure in early vertebrate embryos. Brachyury 2 regulates the expression of genes involved in cellular differentiation, migration, and patterning during embryonic development, ensuring proper formation of the notochord and contributing to the establishment of the vertebrate body plan. The regulation of Brachyury 2 is closely associated with the Wnt signaling pathway, a critical pathway involved in cell fate determination and embryonic development. Brachyury 2 acts downstream of Wnt signaling, where the activation of Wnt leads to the stabilization of β-catenin. Stabilized β-catenin translocates into the nucleus and interacts with T-box transcription factors, including Brachyury 2, to modulate the expression of target genes crucial for notochord development.
Inhibition of Brachyury 2 involves disrupting the Wnt pathway, particularly the interactions that stabilize β-catenin and facilitate its nuclear translocation. Chemical inhibitors like GSK-3 Inhibitor XVI and LY2090314 target GSK3, a kinase that phosphorylates and marks β-catenin for degradation. Inhibition of GSK3 leads to the stabilization of β-catenin, altering downstream gene expression and indirectly modulating Brachyury 2 levels through the Wnt pathway. Similarly, compounds like XAV939 and JW74 interfere with β-catenin/TCF interactions, preventing the transcriptional activity of the β-catenin/TCF complexes and indirectly modulating Brachyury 2 expression. Tankyrase inhibitors such as LGK974 and G007-LK indirectly impact Brachyury 2 by blocking tankyrase activity, stabilizing Axin, and promoting the degradation of β-catenin. This disrupts Wnt signaling and influences Brachyury 2 levels through alterations in the stability and availability of β-catenin. These inhibitors showcase the intricate interplay between Wnt signaling and Brachyury 2, providing insights into potential strategies for modulating Brachyury 2 expression during embryonic development and in various pathological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $153.00 $520.00 | 4 | |
GSK3 inhibitor influencing the Wnt pathway, indirectly affecting brachyury 2. Suppresses GSK3 activity, leading to the stabilization of β-catenin, which influences downstream gene expression and indirectly modulates brachyury 2 levels through the Wnt pathway. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Tankyrase inhibitor affecting the Wnt pathway, indirectly influencing brachyury 2. Blocks tankyrase activity, stabilizing Axin and promoting the degradation of β-catenin, thereby modulating gene expression and indirectly impacting brachyury 2 through the Wnt pathway. | ||||||
LY2090314 | 603288-22-8 | sc-507359 | 5 mg | $175.00 | ||
GSK-3 inhibitor influencing the Wnt pathway, indirectly affecting brachyury 2. Modulates β-catenin degradation, leading to downstream changes in gene expression that indirectly modulate brachyury 2 levels by influencing the Wnt pathway. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $352.00 $1270.00 | 2 | |
Porcupine inhibitor disrupting Wnt ligand secretion, indirectly influencing brachyury 2. Prevents Wnt ligand palmitoylation, leading to altered Wnt signaling and downstream changes in gene expression that indirectly modulate brachyury 2 levels through the Wnt pathway. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
Wnt signaling inhibitor blocking Wnt ligand secretion, indirectly influencing brachyury 2. Prevents Wnt ligand palmitoylation, leading to altered Wnt signaling and downstream changes in gene expression that indirectly modulate brachyury 2 levels through the Wnt pathway. | ||||||
PRI-724 | 1422253-38-0 | sc-507535 | 25 mg | $255.00 | ||
CBP inhibitor affecting the Wnt/β-catenin pathway, indirectly influencing brachyury 2. Disrupts the interaction between β-catenin and CBP, leading to altered gene expression and indirectly modulating brachyury 2 levels through the Wnt/β-catenin pathway. | ||||||
JW 74 | 863405-60-1 | sc-507506 | 5 mg | $168.00 | ||
β-catenin/TCF interaction inhibitor affecting the Wnt pathway, indirectly influencing brachyury 2. Disrupts the interaction between β-catenin and TCF, leading to altered gene expression and indirectly modulating brachyury 2 levels through the Wnt pathway. | ||||||
KY02111 | 1118807-13-8 | sc-397043 sc-397043A | 5 mg 25 mg | $79.00 $336.00 | ||
Wnt/β-catenin pathway inhibitor disrupting β-catenin/TCF interaction, indirectly affecting brachyury 2. Alters gene expression patterns by preventing the transcriptional activity of β-catenin/TCF complexes, indirectly modulating brachyury 2 levels through the Wnt pathway. | ||||||
β-Catenin/Tcf Inhibitor, FH535 | 108409-83-2 | sc-221398 sc-221398A | 10 mg 50 mg | $178.00 $367.00 | 7 | |
β-catenin/TCF interaction inhibitor affecting the Wnt pathway, indirectly influencing brachyury 2. Disrupts the interaction between β-catenin and TCF, leading to altered gene expression and indirectly modulating brachyury 2 levels through the Wnt pathway. | ||||||
IWR-1-endo | 1127442-82-3 | sc-295215 sc-295215A | 5 mg 10 mg | $82.00 $132.00 | 19 | |
Axin stabilization inhibitor affecting the Wnt pathway, indirectly influencing brachyury 2. Alters Wnt signaling by preventing Axin stabilization, leading to downstream changes in gene expression that indirectly modulate brachyury 2 levels through the Wnt pathway. | ||||||